Icahn hires on gene therapy legend—and big biotech disruptor—Richard Mulligan as Bristol-Myers rumors simmer
Back in 2010, when Carl Icahn was spooking Henri Termeer and the management of Genzyme, the heavyweight activist investor sent over a list of hand …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
